What SEC filings does Regencell Bioscience Holdings Limited submit to the SEC?

Regencell Bioscience Holdings Limited (RGC) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about RGC?

A Form 4 for RGC discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Regencell Bioscience Holdings Limited?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for RGC?

The 10-K is Regencell Bioscience Holdings Limited's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all RGC SEC filings directly on EDGAR?

You can view all historical Regencell Bioscience Holdings Limited filings on the SEC EDGAR company page for RGC. Each filing card on this page links directly to the original SEC document.

How often does Regencell Bioscience Holdings Limited file with the SEC?

Regencell Bioscience Holdings Limited files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling RGC shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

RGC SEC Filing News — Regencell Bioscience Holdings Limited

Latest SEC filings for Regencell Bioscience Holdings Limited (RGC) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-05-29.

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $4.7B CIK: 1829667

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by Regencell Bioscience Holdings Limited. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

Insider Transactions 2 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 2 filings in this group are Form 4s for Regencell Bioscience Holdings Limited.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 2 insider filings shown, the breakdown is 2 disposition to issuer. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Disposition to issuer ×2: Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Form 4 Disposition to issuer Tax / Compensation Filing 2026-05-29

RGC insider Form 4 filed for equity award, exercise, or tax withholding

LO WILLIAM WING YAN DR (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer derivative · Stock option (right to purchase)	70,600	—	—

Filing: Form 4 (Insider Transaction) Insider: LO WILLIAM WING YAN DR (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Disposition to issuer Tax / Compensation Filing 2026-05-29

RGC insider Form 4 filed for equity award, exercise, or tax withholding

HUI EVANA YEE WAH (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer derivative · Stock option (right to purchase)	19,000	—	—

Filing: Form 4 (Insider Transaction) Insider: HUI EVANA YEE WAH (Director)

View on SEC EDGAR → Open Filing Document →

How we classify Regencell Bioscience Holdings Limited's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on RGC. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — RGC SEC Filings

More Tools for RGC

RGC Full Stock Analysis RGC Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper RGC analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the RGC stock analysis page.

RGC Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer